Edwards Lifesciences SEC filings, summarized
We read every Edwards Lifesciences 8-K filing and insider trade the night it hits SEC EDGAR, and turn it into a two-minute plain-English summary.
Track EW in your inbox
Add Edwards Lifesciences to your watchlist — free, every morning.
Recent filings
Edwards Lifesciences Raises 2026 Guidance After 13.6% Q2 Sales Growth
Edwards Lifesciences reported second-quarter 2026 sales of $1.74 billion for the quarter ended June 30, up 13.6% from a year earlier, with diluted EPS of…
Edwards filed an 8‑K (Item 9.01) on Feb 10, 2026: Exhibit 99.1 is a press release reporting Q4 2025…
Edwards filed an 8‑K (Item 9.01) on Feb 10, 2026: Exhibit 99.1 is a press release reporting Q4 2025 financial results; Exhibit 104 is the Inline XBRL cover…
Edwards Lifesciences ($EW) issued a press release on Feb 10, 2026 reporting Q4 2025 financial results; the…
Edwards Lifesciences ($EW) issued a press release on Feb 10, 2026 reporting Q4 2025 financial results; the release is furnished as Exhibit 99.1 to Form 8‑K.…
Edwards Lifesciences filed an 8‑K (Item 9.01) on Jan 12, 2026 — Exhibit 99.1: Press Release dated Jan 9,…
Edwards Lifesciences filed an 8‑K (Item 9.01) on Jan 12, 2026 — Exhibit 99.1: Press Release dated Jan 9, 2026; Exhibit 104: Inline XBRL cover page.…
Jan 9, 2026 — U.S.
Jan 9, 2026 — U.S. District Court (D.C.) granted the FTC’s motion for an injunction blocking Edwards Lifesciences’ proposed acquisition of JenaValve;…